Nektar Therapeutics
NKTR8.790USD
+8.123+1219.82%
Handelsschluss 06/09, 16:00（ET）Kurse um 15 Minuten verzögert
1.64BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Nektar Therapeutics Unternehmen
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Unternehmensinformationen
Unternehmens-codeNKTR
Name des UnternehmensNektar Therapeutics
IPO-datumMay 03, 1994
Gegründet am1998
CEOMr. Howard W. Robin
Anzahl der mitarbeiter61
WertpapierartOrdinary Share
GeschäftsjahresendeMay 03
Addresse455 Mission Bay Boulevard South
StadtSAN FRANCISCO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94158
Telefon18554826587
Websitehttps://www.nektar.com/
Unternehmens-codeNKTR
IPO-datumMay 03, 1994
Gegründet am1998
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.40K
-2.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
18.08K
-3.80%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Corey Davis
Corey Davis
Managing Director
Managing Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.40K
-2.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
18.08K
-3.80%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Corey Davis
Corey Davis
Managing Director
Managing Director
--
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Sat, May 17
Update-Zeit: Sat, May 17
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.04%
The Vanguard Group, Inc.
6.61%
Nantahala Capital Management, LLC
4.19%
Acadian Asset Management LLC
3.92%
Eventide Asset Management, LLC
3.57%
Other
74.66%
Aktionärsstatistik
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.04%
The Vanguard Group, Inc.
6.61%
Nantahala Capital Management, LLC
4.19%
Acadian Asset Management LLC
3.92%
Eventide Asset Management, LLC
3.57%
Other
74.66%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
24.81%
Investment Advisor
24.76%
Hedge Fund
15.56%
Research Firm
1.46%
Individual Investor
1.29%
Family Office
0.30%
Bank and Trust
0.11%
Pension Fund
0.08%
Venture Capital
0.03%
Other
31.58%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
395
136.30M
73.24%
-65.37M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
2022Q4
560
175.49M
93.38%
-32.58M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
13.33M
7.16%
+154.21K
+1.17%
Dec 31, 2024
The Vanguard Group, Inc.
12.33M
6.62%
-792.77K
-6.04%
Dec 31, 2024
Nantahala Capital Management, LLC
7.81M
4.2%
+3.70M
+90.02%
Dec 31, 2024
Acadian Asset Management LLC
7.20M
3.87%
+1.55M
+27.34%
Dec 31, 2024
Eventide Asset Management, LLC
6.65M
3.57%
-2.75M
-29.26%
Dec 31, 2024
PRIMECAP Management Company
5.54M
2.98%
-372.07K
-6.29%
Dec 31, 2024
Renaissance Technologies LLC
3.91M
2.1%
+583.15K
+17.52%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.96M
2.13%
-5.50K
-0.14%
Dec 31, 2024
TCG Crossover Management, LLC
4.00M
2.15%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Fri, Jun 6
Update-Zeit: Fri, Jun 6
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.52%
iShares Micro-Cap ETF
Anteil0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.02%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
